Imcivree® (setmelanotide) – New orphan indication
June 16, 2022 - Rhythm Pharmaceuticals announced the FDA approval of Imcivree (setmelanotide), for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS).
Top